| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | -100.0% |
| R&D Expense | $43K | -99.5% |
| SG&A Expense | $3.5M | -47.4% |
| Operating Income | -$4.0M | +90.2% |
| Pre-tax Income | -$1.0M | +95.7% |
| Income Tax | $0 | -100.0% |
| Net Income | -$1.0M | +95.7% |
| EPS (Basic) | -$0.08 | +95.8% |
| EPS (Diluted) | -$0.08 | +95.8% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $14.7M | -22.2% |
| Current Assets | $15.4M | -22.1% |
| Total Assets | $15.4M | -22.1% |
| Current Liabilities | $3.6M | -49.3% |
| Stockholders' Equity | $11.9M | -7.0% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$4.4M | +86.2% |
| Capital Expenditures | $0 | -100.0% |
| Investing Cash Flow | $167K | -99.3% |
| Financing Cash Flow | $0 | -100.0% |
| Free Cash Flow | -$4.4M | +86.2% |